Brought to you by 
GSK licenses Roche's late-stage osteoporosis drug
Dec 2001
Executive Summary
GlaxoSmithKline licensed exclusive worldwide co-development and co-promotion rights, excluding Japan, to Roche's ibandronate, which is in Phase III trials to treat and prevent postmenopausal osteoporosis.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
- Co-Promotion
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GSK licenses Roche's late-stage osteoporosis drug
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice